april
us
secretari
health
human
servic
hh
tommi
thompson
request
pharmaceut
compani
provid
sampl
compound
may
effect
sar
us
nation
institut
health
nih
nih
current
test
approxim
antivir
compound
aggress
screen
program
identifi
potenti
treatment
sar
addit
number
compani
recent
announc
develop
novel
agent
treat
sar
infect
see
tabl
howev
major
agent
still
undergo
preclin
evalu
even
us
fda
regulatori
bodi
expedit
develop
approv
process
unlik
commerci
avail
near
futur
thu
best
hope
immedi
futur
may
lie
antivir
agent
alreadi
approv
extens
test
viral
diseas
thymalfasin
synthet
version
polypeptid
protein
fragment
found
natur
circul
produc
bodi
thymu
gland
zadaxin
immunomodul
stimul
immun
system
cell
natur
killer
cell
zadaxin
regist
countri
princip
treatment
hepat
b
hepat
c
viru
infect
vaccin
adjuv
may
sciclon
pharmaceut
inc
report
sarsrel
export
sale
china
expect
drive
sale
zadaxin
million
second
quarter
compar
revenu
million
first
quarter
million
report
second
quarter
sever
compound
alreadi
clinic
studi
indic
identifi
potenti
treatment
sar
hemispherx
biopharma
inc
sever
program
target
sar
use
lead
compound
alferon
n
natur
sourc
multispeci
product
mismatch
doublestrand
rna
experiment
product
act
potenti
immunomodul
antivir
program
assess
effect
alferon
n
ampligen
alon
combin
sar
coronaviru
nihsponsor
studi
potenti
therapi
sar
identifi
ampligen
unusu
high
consist
antivir
activ
human
coronaviru
pathogen
implic
caus
agent
diseas
ampligen
demonstr
high
potenc
low
concentr
favor
safeti
profil
anoth
compani
hope
nih
test
product
immuneregen
bioscienc
inc
biotechnolog
compani
engag
research
develop
applic
use
modifi
substanc
p
natur
occur
immunomodul
compani
initi
focus
develop
proprietari
compound
homspera
treatment
acut
radiat
syndrom
ar
acut
respiratori
distress
syndrom
ard
sinc
deterior
lung
line
caus
peopl
die
pneumonia
immuneregen
research
suggest
homspera
may
role
treat
sar
pfizer
inc
provid
number
experiment
compound
us
govern
test
coronaviru
includ
rhinoviru
proteas
inhibitor
ag
ruprintrivir
pfizer
suspend
clinic
develop
ruprintrivir
treatment
cold
phase
ii
stage
articl
publish
onlin
scienc
may
suggest
inhibit
viral
proteas
may
key
develop
treatment
sar
compound
ag
may
therefor
form
basi
drug
effect
diseas
combimatrix
corpor
produc
pool
small
interf
rna
sirna
molecul
direct
specif
gene
sar
coronaviru
collabor
us
nation
institut
allergi
infecti
diseas
niaid
us
armi
medic
research
institut
infecti
diseas
usamriid
compani
conduct
initi
screen
sirna
sampl
sar
coronaviru
combimatrix
microarray
platform
technolog
enabl
rapid
prepar
custom
sirna
molecul
base
publish
sequenc
sar
viru
compani
research
target
two
gene
believ
regul
viral
replic
rnadepend
rna
polymeras
ntpasehelicas
domain
result
approxim
potenti
drug
combimatrix
file
patent
specif
molecul
could
becom
drug
sar
plan
offer
drug
candid
partner
complet
preclin
clinic
develop
molecul
other
combimatrix
develop
use
platform
technolog
show
efficaci
initi
test
celsci
corpor
anoth
compani
cooper
niaid
usamriid
sign
agreement
institut
test
immunemodul
peptid
number
infecti
diseas
includ
sar
test
conduct
determin
whether
could
use
potenti
treatment
andor
prevent
agent
diseas
avi
biopharma
inc
also
work
niaid
compani
provid
experiment
antisens
drug
target
sar
coronaviru
niaid
laboratori
test
secretari
thompson
also
met
major
vaccin
manufactur
glaxosmithklin
wyeth
merck
co
aventispasteur
april
urg
test
vaccin
coronavirus
also
sever
compani
develop
novel
vaccin
sar
viru
see
tabl
genvec
inc
form
collabor
research
develop
agreement
crada
vaccin
research
center
niaid
vrcniaid
develop
vaccin
sar
use
compani
proprietari
adenovir
vector
technolog
crada
complementari
fund
contract
vrcniaid
construct
produc
adenovirusbas
sar
vaccin
agreement
govern
preclin
collabor
evalu
develop
adenovir
vector
express
modifi
sar
gene
vrcniaid
test
preclin
vaccin
candid
preclin
model
anoth
vaccin
preclin
develop
generex
biotechnolog
corpor
antigen
express
inc
vaccin
util
generex
proprietari
depot
drug
deliveri
formul
technolog
antigen
express
contribut
proprietari
ii
protein
suppress
iikey
peptid
vaccineenhanc
technolog
antigen
express
develop
novel
therapeut
vaccin
cancer
infecti
diseas
platform
technolog
greatli
enhanc
thelper
cell
respons
result
strong
antibodi
cytotox
cellular
respons
thelper
cell
also
mediat
immunolog
memori
key
develop
longterm
diseasefre
respons
june
generex
announc
agreement
principl
acquir
share
privat
own
antigen
express
exchang
generex
share
evidenc
commit
develop
rapid
diagnost
test
quick
accur
detect
sar
half
stori
frost
sullivan
analyst
annabel
entress
comment
sale
sar
diagnost
expect
act
long
term
revenu
gener
diagnost
industri
fact
roch
expect
make
million
test
although
potenti
revenu
small
compar
hivaid
exampl
compani
still
rush
forefront
discoveri
diagnost
note
entress
global
compani
current
work
sar
diagnost
compani
list
tabl
midmay
abbott
laboratori
commenc
worldwid
market
distribut
agreement
artu
gmbh
believ
first
commerci
pcrbase
test
detect
form
coronaviru
link
sar
hamburgbas
biotechnolog
compani
artu
develop
viru
detect
assay
togeth
bernhardnocht
institut
hamburg
germani
institut
part
research
network
identifi
viru
caus
sar
base
discov
genet
sequenc
bernhardnocht
institut
develop
realtim
pcr
diagnost
test
produc
result
within
hour
test
artu
develop
readytous
system
hpacoronaviru
rt
pcr
reagent
launch
asia
europ
midapril
term
deal
artu
manufactur
test
abbott
market
distribut
initi
use
north
america
uk
germani
austria
abbott
also
help
artu
submit
test
fda
market
distribut
molecular
diagnost
allianc
celera
diagnost
june
vaxim
inc
identifi
synthes
peptid
sar
viral
protein
name
confirm
bind
specif
serum
antibodi
sarsrecov
patient
vaxim
also
success
integr
compani
proprietari
carrier
platform
develop
sar
pointofcar
test
kit
name
test
take
minut
perform
contrari
exist
test
method
employ
tradit
technolog
take
hour
test
requir
much
less
time
major
advantag
safe
use
synthet
peptid
captur
sar
antibodi
instead
requir
use
sar
protein
viru
highli
contagi
vaxim
also
look
appli
new
technolog
develop
promis
vaccin
therapeut
solut
sar
midjun
prodess
inc
complet
develop
molecular
test
base
multiplex
technolog
detect
coronaviru
caus
sar
assay
detect
sar
viru
analyz
patient
sampl
presenc
genet
materi
sar
viru
accord
chief
scienc
offic
dr
kelli
henrickson
particularli
difficult
design
genebas
test
newli
discov
organ
sar
viru
lack
genet
data
larg
number
organ
test
fail
take
account
may
ultim
ineffect
detect
broad
rang
clinic
isol
result
fals
neg
result
consequ
prodess
use
multiplex
technolog
target
three
independ
section
sar
genom
given
sar
third
major
subtyp
coronaviru
known
infect
human
test
also
design
detect
two
subtyp
human
coronaviru
known
capabl
help
clinician
distinguish
sar
normal
coronaviru
infect
explain
dr
henrickson
juli
roch
diagnost
announc
worldwid
launch
sar
diagnost
product
test
research
use
test
develop
period
follow
may
deal
roch
diagnost
genom
institut
singapor
jointli
develop
sar
detect
kit
base
roch
polymeras
chain
reaction
pcr
technolog
institut
alreadi
begun
work
develop
primer
set
realtim
pcr
detect
roch
system
genom
institut
singapor
one
institut
sequenc
sar
genom
sever
acut
respiratori
syndrom
sar
respiratori
ill
recent
report
asia
north
america
europ
scientist
us
cdc
laboratori
detect
previous
unrecogn
coronaviru
patient
sar
new
coronaviru
lead
hypothesi
caus
sar
gener
sar
begin
fever
greater
symptom
may
includ
headach
overal
feel
discomfort
bodi
ach
peopl
also
experi
mild
respiratori
symptom
day
sar
patient
may
develop
dri
cough
troubl
breath
treatment
beyond
good
intens
support
care
consist
shown
improv
prognosi
primari
way
sar
appear
spread
close
persontoperson
contact
case
sar
involv
peopl
care
live
someon
sar
direct
contact
infecti
materi
eg
respiratori
secret
person
sar
also
possibl
sar
spread
broadli
air
way
current
known
sourc
us
center
diseas
control
prevent
